Podcast thumbnail for Viremic – Cases in HIV

Viremic – Cases in HIV

Claim This Podcast

by Dr. Eileen Scully & Dr. Christopher Hoffmann

5.0(10 reviews)
26 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Overview

Hosted by Eileen Scully, MD, PhD, and Christopher Hoffmann, MD, MSC, MPH, both HIV specialists at Johns Hopkins, Viremic explores quandaries in adult HIV care. Each case discussion includes medical history and diagnoses, challenges in care and treatment, and key evidence and guidelines that informed clinical decision making. Cases are presented as a composite from the hosts’ clinical practice, with all identifying details removed to protect the privacy of patients. Case discussions are for informational purposes only and not offered as medical or clinical practice advice for patients or clinicians. Any mention of specific medications or commercially available products is a description of use only, not an endorsement. Viremic is produced by the Clinical Guidelines Program, a collaborative effort of the New York State Department of Health AIDS Institute and the Johns Hopkins University Division of Infectious Diseases. Do you have comments or suggestions for future case topics? Email us at viremicpodcast@jh.edu. Please note that we cannot reply to questions about specific cases or medical conditions.

Language

🇺🇲

Publishing Since

7/8/2025

2 verified contact emails on file for Viremic – Cases in HIV

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

Recent Episodes

Episode thumbnail for Case 25. A Few of Our Favorite Vaccines

June 23, 2026

Case 25. A Few of Our Favorite Vaccines

<p>A new-to-you patient—51-yr-old man with HIV since the early 2000s—has spotty vaccine records. How to educate, make recommendations, and avoid too many vaccinations at once? Listen as Chris and Eileen from Johns Hopkins make the case argue for their favorite vaccines among the many recommended for adults with HIV and describe their approaches to patient education, prioritizing based on specific patient needs, and strategizing vaccination schedules.</p><p><strong>Reference: </strong></p><ul><li>Marks KM, Kang M, Umbleja T, et al. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial. JAMA. 2025 Jan 28;333(4):295-306. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39616603/">39616603</a>.</li></ul><p><strong>Related Guidelines and Resources from the NYSDOH AI Clinical Guidelines Program:</strong></p><ul><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations/?mycollection=hiv-care">Immunizations for Adults With HIV</a>; see especially:<ul><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations?mytab=tab_5&amp;mycollection=hiv-care">Hepatitis B Virus (HBV)</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations?mytab=tab_6&amp;mycollection=hiv-care">Human Papillomavirus (HPV)</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations?mytab=tab_8&amp;mycollection=hiv-care">Measles, Mumps, Rubella (MMR)</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations?mytab=tab_12&amp;mycollection=hiv-care">Pneumococcal</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-immunizations?mytab=tab_15&amp;mycollection=hiv-care">Zoster</a></li></ul></li><li><a href="https://www.hivguidelines.org/guideline/hiv-hbv/?mycollection=hepatitis-care">Prevention and Management of Hepatitis B Virus Infection in Adults With HIV</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-hpv/?mycollection=hpv-care">Prevention and Management of Human Papillomavirus Infection in Adults With HIV</a></li><li><a href="https://viremic.org/episodes/case-15-a-pain-in-the-butt-anal-cancer-screening-and-prevention">Viremic Case 15. A Pain in the Butt: Anal Cancer Screening and Prevention</a></li></ul>

Episode thumbnail for Case 24. A Violaceous Situation: Kaposi Sarcoma

June 9, 2026

Case 24. A Violaceous Situation: Kaposi Sarcoma

<p>A 42-yr-old man with AIDS presents feeling unwell, with white spots in his mouth, and scattered violaceous macules on his upper extremities; he has never taken ART. Listen as hosts Eileen Scully and Chris Hoffmann from Hopkins describe their initial work-up for a patient with a CD4 count of 10; discuss symptoms, diagnosis, and treatment of Kaposi sarcoma and other HHV8-related diseases; and remember the historical stigma of KS and the lingering effects of that stigma as they confirm the need to remain KS-aware even in 2026 in the U.S.</p><p><strong>References Cited:</strong></p><ul><li>Bettuzzi T, Lebbe C, Grolleau C. Modern Approach to Manage Patients With Kaposi Sarcoma. J Med Virol. 2025 Mar;97(3):e70294. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40119751/">40119751</a>.</li><li>Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. Human Herpesvirus-8 Disease. Updated April 23, 2025. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-herpesvirus">Available online here</a>. Accessed 5/21/2026.</li></ul><p><strong>Related Guidelines<br>NYSDOH AI Clinical Guidelines Program:</strong></p><ul><li><a href="https://www.hivguidelines.org/guideline/hiv-primary-care/?mycollection=hiv-care">Primary Care for Adults With HIV</a>; see especially Flowchart 3: Initial Visit: New Patient, HIV Confirmed, NOT Taking ART </li><li><a href="https://www.hivguidelines.org/guideline/hiv-iris/?mycollection=hiv-treatment">Management of IRIS</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-art-rapid/?mycollection=hiv-treatment">Rapid ART Initiation</a></li></ul><p><strong>Clinical Info HIV.gov:</strong> </p><ul><li><a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections">HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections</a> – <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-herpesvirus">Human Herpesvirus-8 Disease</a></li></ul><p><strong>Resource:</strong> </p><ul><li>DermNet – <a href="https://dermnetnz.org/topics/kaposi-sarcoma-images">Kaposi sarcoma images</a> </li></ul><p><br></p>

Episode thumbnail for Case 23. Managing Directly (Inter)Acting Medications

May 26, 2026

Case 23. Managing Directly (Inter)Acting Medications

<p>Chris presents a 62-yr-old man with HIV for &gt;30 yrs, with viral suppression and many drug resistance mutations, whose ART must be changed due to a drug-drug interaction, but also for simplification. As part of their discussion, Chris and Eileen review reasons to change ART regimens, and work through the evidence-based options for this patient based on his history and resistance mutations profile.</p><p><strong>References Cited:</strong></p><ul><li>Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017 Sep;4(9):e384-e392. Epub 2017 May 28. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28566227/">28566227</a>.</li><li>Hocqueloux L, Raffi F, Prazuck T, et al. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clin Infect Dis. 2019 Oct 15;69(9):1498-1505. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30601976/">30601976</a>.</li><li>Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022 Jun;9(6):e381-e393. Epub 2022 Apr 20. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35460601/">35460601</a>.</li><li>Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014 Nov 29;384(9958):1942-51. Epub 2014 Aug 4. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25103176/">25103176</a>.</li><li>Severe P, Pierre S, Homeus F, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial. Lancet HIV. 2025 Sep;12(9):e616-e626. Erratum in: Lancet HIV. 2026 Feb;13(2):e84. Erratum in: Lancet HIV. 2026 Feb 24:S2352-3018(26)00037-8. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40883049/">40883049</a>.<p></p></li></ul><p><strong>Related NYSDOH AI Guidelines:</strong></p><ul><li><a href="https://www.hivguidelines.org/guideline/hiv-2nd-line-art/?mycollection=hiv-treatment">Second-Line ART After Treatment Failure or for Regimen Simplification</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-resistance-assays/?mycollection=hiv-treatment">HIV Resistance Assays</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-art-drug-interactions/?mycollection=hiv-treatment">Drug-Drug Interaction Guide: From HIV Prevention to Treatment</a></li><li><a href="https://www.hivguidelines.org/guideline/hiv-monitoring/?mycollection=hiv-treatment">Virologic and Immunologic Monitoring in HIV Care</a></li></ul><p><br></p>

26 total episodes available

Deep-dive analytics for Viremic – Cases in HIV

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Viremic – Cases in HIV?

Hosted by Eileen Scully, MD, PhD, and Christopher Hoffmann, MD, MSC, MPH, both HIV specialists at Johns Hopkins, Viremic explores quandaries in adult HIV care. Each case discussion includes medical history and diagnoses, challenges in care and treatment, and key evidence and guidelines that informed clinical decision making.

Cases are presented as a composite from the hosts’ clinical practice, with all identifying details removed to protect the privacy of patients. Case discussions are for informational purposes only and not offered as medical or clinical practice advice for patients or clinicians. Any mention of specific medications or commercially available products is a description of use only, not an endorsement. Viremic is produced by the Clinical Guidelines Program, a collaborative effort of the New York State Department of Health AIDS Institute and the Johns Hopkins University Division of Infectious Diseases.

Do you have comments or suggestions for future case topics? Email us at viremicpodcast@jh.edu. Please note that we cannot reply to questions about specific cases or medical conditions.

How often does this podcast release new episodes?

This podcast updates daily.

Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

No, this podcast does not typically feature guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.